Johnson & Johnson shares gain momentum as new clinical data confirms ERLEADA plus ADT significantly reduces metastasis and mortality risks in prostate cancer patients compared to surgery alone.
Johnson & Johnson's oncology portfolio is bolstered by new substudy results demonstrating that perioperative apalutamide (ERLEADA) combined with androgen deprivation therapy (ADT) significantly improves patient outcomes. The data indicates a 51% reduction in the risk of metastasis or death compared to immediate surgery alone, reinforcing the clinical efficacy of the drug in prostate cancer treatment.
The regimen demonstrated a 51% lower estimated risk of metastasis or death compared to immediate surgery alone.
Twice as many patients remained free from subsequent treatment at three years when treated with perioperative apalutamide plus ADT compared to surgery alone.
Johnson & Johnson reported positive clinical data for its ERLEADA treatment, demonstrating a 62% reduction in the risk of recurrence or death when combined with ADT versus surgery alone. The substudy also highlighted a 51% lower risk of metastasis, reinforcing the drug's efficacy in the oncology portfolio.
The study demonstrates that perioperative apalutamide plus ADT significantly outperforms surgery alone in reducing metastasis and mortality risks for prostate cancer patients.